Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Aggressive non-Hodgkin Lymphoma
100%
Salvage Therapy
100%
Gemcitabine
100%
Overall Survival
33%
Non-Hodgkin Lymphoma
33%
Dosing Regimen
33%
B Cells
16%
Published Data
16%
Favorable Outcome
16%
Median Overall Survival
16%
Progression-free Survival
16%
Effective Treatment
16%
Progressive Disease
16%
T-cell Lymphoma
16%
Unmet Needs
16%
Complete Response
16%
Reduced Dose
16%
Salvage Regimen
16%
Overall Response Rate
16%
Lymphoma Patients
16%
Stable Disease
16%
Partial Response
16%
Innovative Therapies
16%
Median Progression-free Survival
16%
Anthracyclines
16%
Hematotoxicity
16%
Refractory Disease
16%
Relapsed Lymphoma
16%
Day Range
16%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Salvage Therapy
100%
Gemcitabine
100%
Overall Survival
50%
Disease
33%
Progression Free Survival
33%
Drug Dose Regimen
33%
B Cell
16%
Experimental Therapy
16%
Progressive Disease
16%
T-Cell Lymphoma
16%
Anthracycline
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Gemcitabine
100%
Overall Survival
50%
Disease
50%
Progression Free Survival
33%
T Cell Lymphoma
16%
Anthracycline
16%
Immunology and Microbiology
Overall Survival
100%
Progression Free Survival
66%
Drug Dose Regimen
66%
B Cell
33%
T Cell
33%
Biochemistry, Genetics and Molecular Biology
Gemcitabine
100%
Overall Survival
50%
Progression Free Survival
33%
Drug Dose Regimen
33%
B Cell
16%
T Cell
16%
Anthracycline
16%